Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 9:5:517-23.
doi: 10.2147/ijn.s11643.

Benefit of magnesium-25 carrying porphyrin-fullerene nanoparticles in experimental diabetic neuropathy

Asieh Hosseini  1 , Mohammad Sharifzadeh, Seyed Mahdi Rezayat, Gholamreza Hassanzadeh, Shokoufeh Hassani, Maryam Baeeri, Vahid Shetab-Bushehri, Dmitry A Kuznetsov, Mohammad Abdollahi
Affiliations

Benefit of magnesium-25 carrying porphyrin-fullerene nanoparticles in experimental diabetic neuropathy

Asieh Hosseini et al. Int J Nanomedicine. .

Abstract

Diabetic neuropathy (DN) is a debilitating disorder occurring in most diabetic patients without a viable treatment yet. The present work examined the protective effect of (25)Mg-PMC(16) nanoparticle (porphyrin adducts of cyclohexil fullerene-C60) in a rat model of streptozotocin (STZ)-induced DN. (25)Mg-PMC(16) (0.5 lethal dose(50) [LD(50)]) was administered intravenously in two consecutive days before intraperitoneal injection of STZ (45 mg/kg). (24)Mg-PMC(16) and MgCl(2) were used as controls. Blood 2,3-diphosphoglycerate (2,3-DPG), oxidative stress biomarkers, adenosine triphosphate (ATP) level in dorsal root ganglion (DRG) neurons were determined as biomarkers of DN. Results indicated that 2,3-DPG and ATP decreased whereas oxidative stress increased by induction of DN which all were improved in (25)Mg-PMC(16)-treated animals. No significant changes were observed by administration of (24)Mg-PMC(16) or MgCl(2) in DN rats. It is concluded that in DN, oxidative stress initiates injuries to DRG neurons that finally results in death of neurons whereas administration of (25)Mg-PMC(16) by release of Mg and increasing ATP acts protectively.

Keywords: 25Mg-magnetic isotope effect; adenosine triphosphate; diabetes; nanotechnology; neuropathy; oxidative stress; porphyrin-fullerene nanoparticles.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Protective effects of various forms of magnesium on blood glucose in DN rats after two months. Notes: Data are mean ± SE of six animals. Difference between control and other groups is significant at P < 0.001(aaa). Difference between DN and 25Mg-PMC16 is significant at P < 0.05(b). Abbreviations: DN, diabetic neuropathy; SE, standard error.
Figure 2
Figure 2
Protective effects of various forms of magnesium on weight of DN rats after two months. Notes: Data are mean ± SE of six animals. Difference between control and other groups is significant at P < 0.001(aaa). Difference between DN and 25Mg-PMC16 is significant at P < 0.05(bb). Abbreviations: DN, diabetic neuropathy; SE, standard error.
Figure 3
Figure 3
Protective effects of various forms of magnesium on 2,3-DPG concentration in erythrocytes of DN rats after two months. Notes: Data are mean ± SE of six animals. Difference between control and other groups is significant at P < 0.001(aaa). Difference between DN and 25Mg-PMC16 is significant at P < 0.001(bbb). Abbreviations: DN, diabetic neuropathy; SE, standard error.
Figure 4
Figure 4
Protective effects of various forms of magnesium on ADP/ATP level in DN rats after two months. Notes: Data are mean ± SE of six animals. Difference between control and other groups is significant at P < 0.001(aaa). Difference between DN and 25Mg-PMC16 is significant at P < 0.001(bbb). Abbreviations: ADP/ATP, adenosine diphosphate/adenosine triphospahte; DN, diabetic neuropathy; SE, standard error.
See this image and copyright information in PMC

References

    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. - PubMed
    1. Raymond Azman A. Management of diabetic neuropathy. Malaysian Journal of Medical Science. 2003;10(2):27–30. - PMC - PubMed
    1. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301–314. - PMC - PubMed
    1. Fernyhough P, Huang TJ, Verkhratsky A. Mechanism of mitochondrial dysfunction in diabetic sensory neuropathy. J Peripher Nerv Syst. 2003;8(4):227–235. - PubMed
    1. Douglas W, Zochodne MD. Diabetic Neuropathies. Neuromuscul Disord. 2000;2:23–29.

Publication types

MeSH terms